Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Allogeneic Tumor Cell Vaccine"'
Autor:
Elizabeth M. Jaffee, Dung T. Le, William H. Burns, Robert A. Anders, Elizabeth D. Thompson, Jessica Hoare, Rachel B. Klein, Haihui Cao, Richard A. Burkhart, Rose Parkinson, Carol Judkins, Jennifer N. Durham, Daniel A. Laheru, Ana De Jesus-Acosta, Christopher L. Wolfgang, Jin He, Hao Wang, Amol Narang, Katrina Purtell, Lei Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Data analysis of specimens from prior clinical trials identified the immune co-simulatory molecule CD137 within the tumor microenvironment(TME) of pancreatic ductal adenocarcinoma(PDAC) that remain to be activated following vaccine induced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73c5ed4572c2b7b50304909923023d18
https://doaj.org/article/ecf60ca4c16d4e89b7100a6bd2bc155b
https://doaj.org/article/ecf60ca4c16d4e89b7100a6bd2bc155b
Autor:
Annette Wolf, Joachim Kopp, Bernd Dörken, Anne Flörcken, Georg Lenz, Andre Weilemann, Peter Lenz, Thomas Blankenstein, Michael Grau, Jörg Westermann, Antonio Pezzutto
Publikováno v:
International Journal of Cancer. 136:1814-1826
Tumor-induced immunosuppression remains a major challenge for immunotherapy of cancer patients. To further elucidate why an allogeneic gene-modified [interleukin-7 (IL-7)/CD80-cotransfected] renal cell cancer (RCC) vaccine failed to induce clinically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af438e912b939ac6d3f9b383d35074d8
https://doi.org/10.1002/ijc.29230
https://doi.org/10.1002/ijc.29230
Autor:
Ronan J. Kelly, Giuseppe Giaccone
Publikováno v:
The Cancer Journal. 17:302-308
In lung cancer, early attempts to modulate the immune system via vaccine based therapeutics have to date, been unsuccessful. An improved understanding of tumor immunology has facilitated the production of more sophisticated lung cancer vaccines. It i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3655052277b01dd1e307e179ec14a873
https://doi.org/10.1097/ppo.0b013e318233e6b4
https://doi.org/10.1097/ppo.0b013e318233e6b4
Autor:
Lily Y. Liu, John Nemunaitis, Jodi Cutler, Paul Schwarzenberger, Casey Cunningham, Neil Senzer, Habib Fakhrai, Edward DeVol, Beena O. Pappen, Robert O. Dillman, Phillip B. Maples, Daniel L. Shawler, Padmasini Kumar, Terry Chamberlin, Alex W. Tong, Cody Hamilton
Publikováno v:
Journal of Clinical Oncology. 24:4721-4730
PurposeBelagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that demonstrates enhancement of tumor antigen recognition as a result of transforming growth factor beta-2 inhibition.Patients and MethodsWe performed a randomized, dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e23cce29b5d5ca662d700d1691aed201
https://doi.org/10.1200/jco.2005.05.5335
https://doi.org/10.1200/jco.2005.05.5335
Autor:
A.N. Alexander, E G MacEwen, David M. Vail, M. K. Huelsmeyer, Ann Mitzey, Ilene D. Kurzman, Richard R. Dubielzig
Publikováno v:
Cancer Immunology, Immunotherapy. 55:433-442
A xenogeneic melanoma-antigen-enhanced allogeneic tumor cell vaccine (ATCV) is an appealing strategy for anti-cancer immunotherapy due to its relative ease of production, and the theoretical possibility that presentation of a multiplex of antigens al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0b5d059d522cbcc3cd31346ccbd9f36
https://doi.org/10.1007/s00262-005-0025-6
https://doi.org/10.1007/s00262-005-0025-6
Autor:
Ann E. Haight, Kristine Cooper, Eric Yvon, Charlotte Hirschmann-Jax, Donna Rill, Zhuyong Mei, Susan C. Smith, Andrew M. Davidoff, Douglas Strother, Shannon Inman, Raphael Rousseau, Edwina J. Popek, Laura C. Bowman, Pat Alcoser, Bambi Grilley, Malcolm K. Brenner, Adrian P. Gee
Publikováno v:
Blood. 101:1718-1726
In murine models, transgenic chemokine–cytokine tumor vaccines overcome many of the limitations of single-agent immunotherapy by producing the sequence of T-cell attraction followed by proliferation. The safety and immunologic effects of this appro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62c0802cebdf1b247daf8ecac06e5038
https://doi.org/10.1182/blood-2002-08-2493
https://doi.org/10.1182/blood-2002-08-2493
Publikováno v:
Clinical Breast Cancer. 3:S173-S180
Cancer vaccines are currently a major focus of immunotherapy research. The combination of specific targeting and low levels of toxicity makes vaccination an attractive approach. There are a variety of immunogens that can be employed to vaccinate pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d17701b5952e5f3075d7dc7c3a241d3
https://doi.org/10.3816/cbc.2003.s.008
https://doi.org/10.3816/cbc.2003.s.008
Autor:
Kristof Cuppens, Johan Vansteenkiste
Publikováno v:
Current opinion in oncology. 26(2)
Purpose of review Recent advances in our understanding of cancer immunology resulted in the development of promising therapeutic agents for either nonantigen-specific immunotherapy, for example, monoclonal antibodies targeting immune checkpoints on t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9478f75309c3047edd969bccb1a11182
https://pubmed.ncbi.nlm.nih.gov/24441502
https://pubmed.ncbi.nlm.nih.gov/24441502
Autor:
Dolores J. Schendel, Birgit Stadlbauer, B Dörken, Gerald Willimsky, Ralph Oberneder, Bernhard Frankenberger, Alfons Hofstetter, Heike Pohla, Antonio Pezzutto, Thomas Blankenstein
Publikováno v:
Bone Marrow Transplantation. 25:S83-S87
An allogeneic tumor cell vaccine should display a natural immunogenicity that allows the stimulation of tumor-reactive effector cells in patients. Furthermore, the vaccine should express antigens that are shared by many tumors to which patients are n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c03969b3a1b16e7afdcc44ef6159df
https://doi.org/10.1038/sj.bmt.1702362
https://doi.org/10.1038/sj.bmt.1702362
Autor:
Antonio Pezzutto, Dolores J. Schendel, Heike Pohla, Britta Papier, Bernhard Frankenberger, Elfriede Noessner, Ralph Oberneder, Gerald Willimsky, Joachim Kopp, Thomas Blankenstein
Publikováno v:
Clin. Cancer Res. 11, 1733-1742 (2005)
Purpose: A renal cell carcinoma (RCC) line, RCC-26, has been identified as a suitable candidate for development of an allogeneic tumor cell vaccine based on its expression of a variety of tumor-associated antigens (TAA). To improve immunogenicity, RC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779f77241c1de90cb6b70f797ae1b643
https://pubmed.ncbi.nlm.nih.gov/15755994
https://pubmed.ncbi.nlm.nih.gov/15755994